Payment overview · 2025
General Payments
$955.04
20 reported records · 10 companies
Healthcare provider profile · identity verified
Tenzin Dekyi, NURSE PRACTITIONER
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · EAST ELMHURST, NY · NPI 1295482875
Verified facts
What the public records show
CMS Open Payments records show Tenzin Dekyi, NURSE PRACTITIONER received $955.04 in general payments during 2025 across 20 reported records.
Eisai Inc. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Tagrisso by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INLYTA as an associated drug or biological on 2646 records involving 1964 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Inlyta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 16373 records involving 6981 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Orgovyx by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $207.86 | 21.8% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $205.07 | 21.5% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $152.31 | 15.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $120.38 | 12.6% | 2 | 2025 |
| SEAGEN INC. | Unresolved — no canonical attribution shown | $99.99 | 10.5% | 1 | 2025 |
| ACCORD HEALTHCARE, INC. | Unresolved — no canonical attribution shown | $67.14 | 7.0% | 1 | 2025 |
| PROGENICS PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $30.26 | 3.2% | 1 | 2025 |
| Blue Earth Diagnostics | Unresolved — no canonical attribution shown | $25.22 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.14 | 2.6% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $21.67 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $665.10 | 17 |
| Education | $289.94 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $207.86 | 4 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $205.07 | 5 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $152.31 | 3 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $120.38 | 2 | 2025 |
Source payment records
|
|||||
| Camcevi Normalized: camcevi |
Drug | ACCORD HEALTHCARE, INC. | $67.14 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $62.31 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $43.56 | 2 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $35.71 | 1 | 2025 |
Source payment records
|
|||||
| PYLARIFY Normalized: pylarify |
Drug | PROGENICS PHARMACEUTICALS, INC. | $30.26 | 1 | 2025 |
Source payment records
|
|||||
| POSLUMA Normalized: posluma |
Drug | Blue Earth Diagnostics | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | INLYTA open payments reported associated product |
CMS Open Payments — General Payments 2646 supporting records · 1964 recipient NPIs · example record 1228795917 |
Inlyta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 16373 supporting records · 6981 recipient NPIs · example record 1228794230 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 170 | 43 |
| Abiraterone Acetate | Abiraterone Acetate | 150 | 28 |
| Orgovyx | Relugolix | 55 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 26 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 40 | 18 |
| Loperamide | Loperamide Hcl | 37 | 14 |
| Eliquis | Apixaban | 36 | 14 |
| Folic Acid | Folic Acid | 25 | 13 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Inlyta | Axitinib | 20 | suppressed |
| Dexamethasone | Dexamethasone | 18 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Gabapentin | Gabapentin | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Tagrisso | Osimertinib Mesylate | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Xtandi | Enzalutamide | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Bicalutamide | Bicalutamide | 11 | 11 |
| Lidocaine | Lidocaine | 11 | suppressed |
| Zarxio | Filgrastim-Sndz | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $955.04 · 20 records | Eisai Inc. | AKEEGA, BALVERSA, Camcevi, ERLEADA, Enhertu, KEYTRUDA, KEYTRUDA QLEX, LYNPARZA, Lenvima, PADCEV, POSLUMA, PYLARIFY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error